CytomX - Model BMS-986288 - CTLA-4-Directed Probody Therapeutic

Bristol Myers Squibb is enrolling patients in the dose escalation phase of a Phase 1/2a clinical trial (NCT03994601) of a second anti-CTLA-4 Probody, BMS-986288, based on a modified version of Yervoy® (ipilimumab), to evaluate a CTLA-4-directed Probody therapeutic alone or in combination with Opdivo® (nivolumab) in patients with selected advanced solid cancers. CTLA-4, a clinically validated inhibitory immune checkpoint protein, is the most advanced target from the 12-target collaboration.